Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
Subscribe To Our Newsletter & Stay Updated